To the full analysis
Buyback calculator for Cogent Biosciences
Cogent Biosciences stock: key metrics
COGTCogent Biosciences had an operating margin of 0% and a return on invested capital (ROIC) of −45.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2015 | 100.0% | −220.8% | −220.8% |
| 2016 | 100.0% | −300.1% | −285.2% |
| 2017 | 100.0% | −312.8% | −304.9% |
| 2018 | 100.0% | −369.9% | −354.8% |
| 2019 | 99.8% | −143.0% | −134.6% |
| 2020 | −227.0% | −1,044.3% | −950.4% |
| 2021 | no data | no data | no data |
| 2022 | no data | no data | no data |
| 2023 | no data | no data | no data |
| 2024 | no data | no data | no data |
| 2025 | no data | no data | no data |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2015 | −9.5% | −6.0% | −7.0% |
| 2016 | −34.6% | −19.5% | −24.0% |
| 2017 | −90.1% | −39.5% | −51.9% |
| 2018 | −57.3% | −57.5% | −40.2% |
| 2019 | −95.3% | −52.3% | −61.3% |
| 2020 | −31.9% | −47.4% | −29.8% |
| 2021 | −33.7% | −26.4% | −31.1% |
| 2022 | −54.8% | −47.8% | −46.6% |
| 2023 | −74.6% | −59.9% | −61.4% |
| 2024 | −99.8% | −79.6% | −78.0% |
| 2025 | −51.7% | −45.9% | −35.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.